Prof Louise Emmett is the Director of Theranostics and Nuclear medicine at St Vincent’s Hospital Sydney, Australia with a sub-specialty interest in the imaging and therapy of prostate cancer. She undertook her medical undergraduate training in Auckland, New Zealand, prior to completing her specialty training in Nuclear Medicine in Sydney, and a post specialty Nuclear Cardiology fellowship in Toronto, Canada.

She commenced work in Nuclear medicine and PET at St Vincent’s Hospital, Sydney in 2012,  initiating radio-pharmacy production of multiple new imaging and therapy peptides on the St Vincent’s campus for clinical and research evaluation. She is a principal investigator for a number of national prospective trials including the PRIMARY and PRIMARYII trials (PSMA + MRI in prostate diagnosis), LuPIN trial ( Lu PSMA+ Idronoxil), ENZAp (phase II randomised trial of enzalutamide vs enzalutamide + Lu PSMA), in addition to running phase I imaging trials in new theranostic agents.